Multiphasic Oral Contraceptive Regimen for Cycle Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Extended monophasic oral contraceptive regimens suffer from poor initial cycle control and increased risk of breakthrough bleeding, leading to functional amenorrhea, which is psychologically distressing and unacceptable.
Innovation Solution
A multiphasic contraceptive method involving sequential administration of Phase I, II, and III compositions with varying estrogen and progestogen doses, where the intermediate phase has a higher estrogen dose than the initial and final phases, ensuring consistent endometrial integrity and reduced breakthrough bleeding, and optionally includes a Phase IV placebo or non-steroidal component for extended cycle control.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If monophasic oral contraceptives are administered for an extended period, then contraceptive efficacy is maintained, but menstrual cycle control deteriorates and breakthrough bleeding increases
Solution Approach 1:
The patent applies the dynamics principle by transitioning from a static monophasic regimen to a dynamic multiphasic regimen where hormone doses vary across different phases. The contraceptive contains three distinct phases with progressively decreasing estrogen and progestin doses, allowing the formulation to adapt to changing physiological needs during the extended cycle, thereby maintaining both efficacy and cycle control.
Solution Approach 2:
The patent implements parameter changes by systematically varying the concentrations of estrogen and progestin across three phases. Phase I contains highest doses, Phase II contains intermediate doses, and Phase III contains lowest doses. This gradual parameter adjustment maintains endometrial stability and prevents breakthrough bleeding while preserving contraceptive efficacy throughout the extended 98-day regimen.
2Object-affected harmful factors
If estrogen dose is reduced to minimize blood clotting side effects, then safety improves, but breakthrough bleeding increases
Solution Approach 1:
The patent resolves this contradiction through parameter changes by implementing a multiphasic dosing strategy. The estrogen dose is reduced across phases to minimize blood clotting risk, while the intermediate Phase II maintains sufficiently high estrogen levels to prevent breakthrough bleeding. This staged parameter adjustment balances safety and efficacy.
Solution Approach 2:
The patent applies periodic action by structuring the extended cycle into three distinct phases with different hormone levels. This periodic variation in dosing allows the body to adapt to reduced estrogen exposure while maintaining adequate levels during critical periods, thereby preventing both thrombotic events and breakthrough bleeding.
3Productivity
If extended cycle regimen is implemented, then number of menstrual cycles is reduced, but functional amenorrhea increases causing psychological distress
Solution Approach 1:
The patent applies periodic action by incorporating scheduled withdrawal bleeds at the end of each 98-day extended cycle. This periodic reset allows users to experience predictable, controlled menstruation, preventing the psychological distress of unpredictable functional amenorrhea while still reducing the overall number of cycles compared to traditional monthly regimens.
Solution Approach 2:
The patent implements feedback by providing users with predictable, scheduled withdrawal bleeding that serves as a physiological signal confirming non-pregnancy. This feedback mechanism addresses psychological concerns by providing reassurance while maintaining the efficiency benefits of the extended cycle regimen.
Data Source
AI summary
A multiphasic method of contraception provides for sequentially administering to a female of child bearing age: (a) a Phase I composition containing a progestogen and an estrogen for about 4 to about 7 days; (b) a Phase II composition containing a progestogen and an estrogen for about 8 to about 16 days; (c) a Phase III composition containing a progestogen and an estrogen for about 4 to about 7 days; and (d) optionally, a Phase IV composition which is a placebo or a non-steroidal component, wherein the ethinyl estradiol equivalent amount of estrogen in the Phase II composition is at least 5 mcg greater than the ethinyl estradiol equivalent amount of estrogen in each of the Phase I and III compositions. Preferably the sequential administration is repeated the day following the completion of the administration of the Phase III compositions providing an extended cycle multiphasic oral contraceptive method.